IMPI: Prednisolone for tuberculous pericarditis

Tuberculous pericarditis is associated with high morbidity and mortality. This study included 1400 patients with definite or probable tuberculous pericarditis to receive prednisolone or placebo for 6 weeks. Two-thirds of patients had concomitant HIV infection. The primary end point was a composite of death, tamponade, or constrictive pericarditis. No significant differences between those who received corticosteroids versus those receiving placebo (23, 8% versus 24, 5%; p=0.66) were observed. 


Bongani M. Mayosi
2014-09-02

Original title: IMPI Steroid Study: A Trial of Adjunctive Prednisolone in Tuberculous Pericarditis.

More articles by this author

IBIS 4: intensive treatment with statins after ST-segment elevation myocardial infarction

Statins may help stabilize the atherosclerotic plaque in acute myocardial infarction. 103 patients who underwent primary angioplasty followed by coronary intravascular ultrasound (IVUS) in...

AMIO-CAT: Amiodarone after ablation of atrial fibrillation

Early recurrence of atrial fibrillation after ablation is an experience that discourages patients. The aim of this study was to analyze the overall effectiveness...

X-Vert: Rivaroxaban in patients with atrial fibrillation undergoing elective cardioversion

This study included 1504 patients with atrial fibrillation and indication for elective electrical cardioversion who were randomized to rivaroxaban (n = 1002) versus Marevan...

STICS: perioperative statins to prevent atrial fibrillation

The aim of this study was to test whether perioperative treatment with rosuvastatin 20 mg could prevent the incidence of postoperative atrial fibrillation and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...